Harmony Bioscience News Today

HRMY earnings call for the period ending March 31, 2024.

BioPharma

The FDA has granted Orphan Drug designation to Harmony Bioscience’s pitolisant for the treatment of Prader-Willi syndrome.

Phase 2 study results reveal pitolisant significantly improved daytime sleepiness and fatigue in myotonic dystrophy type 1 patients.

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) – Equities research analysts at Cantor Fitzgerald boosted their FY2024 earnings per share (EPS) estimates for Harmony Biosciences in a research report issued to clients and investors on Wednesday, November 1st. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings per share of […]

The US Patent Office has denied a Petition for Reexamination concerning a patent covering the active ingredient in Wakix (pitolisant). 

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Free Report) – Cantor Fitzgerald decreased their FY2023 earnings estimates for shares of Harmony Biosciences in a research note issued to investors on Wednesday, August 2nd. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings of $2.31 per share for the year, down from their […]

Astria Therapeutics (NASDAQ:ATXS – Get Free Report) and Harmony Biosciences (NASDAQ:HRMY – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, earnings, analyst recommendations, risk, profitability, valuation and institutional ownership. Risk and Volatility Astria Therapeutics has a […]

Alterity Therapeutics (NASDAQ:ATHE – Get Rating) and Harmony Biosciences (NASDAQ:HRMY – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, dividends, earnings, valuation, profitability, risk and institutional ownership. Volatility and Risk Alterity Therapeutics has a beta of 1.2, […]

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY – Get Rating) – Cantor Fitzgerald raised their FY2023 EPS estimates for shares of Harmony Biosciences in a note issued to investors on Wednesday, May 3rd. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will post earnings per share of $2.36 for the year, up from their previous […]